Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ROBERT KRANCE and CARIDAD MARTINEZ.
ROBERT KRANCE
Connection Strength
4.189
CARIDAD MARTINEZ
  1. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
    View in: PubMed
    Score: 0.922
  2. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83.
    View in: PubMed
    Score: 0.416
  3. HSCT corrects primary immunodeficiency and immune dysregulation in patients with POMP-related autoinflammatory disease. Blood. 2021 11 11; 138(19):1896-1901.
    View in: PubMed
    Score: 0.208
  4. Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020 03; 188(6):e84-e87.
    View in: PubMed
    Score: 0.184
  5. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
    View in: PubMed
    Score: 0.179
  6. Immunoglobulin prophylaxis in pediatric hematopoietic stem cell transplant. Pediatr Blood Cancer. 2018 12; 65(12):e27348.
    View in: PubMed
    Score: 0.167
  7. Therapeutic Plasma Exchange does not Improve Renal Function in Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy: An Institutional Experience. Biol Blood Marrow Transplant. 2019 01; 25(1):157-162.
    View in: PubMed
    Score: 0.166
  8. Allogeneic hematopoietic cell transplant following crizotinib monotherapy for relapsed/refractory anaplastic large cell lymphoma. Pediatr Transplant. 2018 08; 22(5):e13210.
    View in: PubMed
    Score: 0.163
  9. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650.
    View in: PubMed
    Score: 0.162
  10. Intravesicular cidofovir for BK hemorrhagic cystitis in pediatric patients after hematopoietic stem cell transplant. Pediatr Transplant. 2018 05; 22(3):e13141.
    View in: PubMed
    Score: 0.160
  11. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
    View in: PubMed
    Score: 0.158
  12. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72.
    View in: PubMed
    Score: 0.131
  13. Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51.
    View in: PubMed
    Score: 0.098
  14. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81.
    View in: PubMed
    Score: 0.093
  15. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 May 08.
    View in: PubMed
    Score: 0.062
  16. Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab. Pediatr Hematol Oncol. 2024 May; 41(4):260-272.
    View in: PubMed
    Score: 0.060
  17. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 Feb; 30(2):217-227.
    View in: PubMed
    Score: 0.060
  18. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting. Clin Cancer Res. 2023 01 17; 29(2):324-330.
    View in: PubMed
    Score: 0.056
  19. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
    View in: PubMed
    Score: 0.054
  20. Acute exacerbation of graft-versus-host disease following SARS-CoV2 infection after hematopoietic stem cell transplant in two pediatric patients. Pediatr Blood Cancer. 2022 10; 69(10):e29661.
    View in: PubMed
    Score: 0.053
  21. Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
    View in: PubMed
    Score: 0.053
  22. Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children's Hospital experience. Bone Marrow Transplant. 2021 11; 56(11):2797-2803.
    View in: PubMed
    Score: 0.051
  23. Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant. 2020 05; 26(5):911-919.
    View in: PubMed
    Score: 0.046
  24. "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Adv. 2019 09 10; 3(17):2571-2580.
    View in: PubMed
    Score: 0.045
  25. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Adv. 2019 07 23; 3(14):2057-2068.
    View in: PubMed
    Score: 0.044
  26. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
    View in: PubMed
    Score: 0.041
  27. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431.
    View in: PubMed
    Score: 0.040
  28. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.039
  29. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1.
    View in: PubMed
    Score: 0.035
  30. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
    View in: PubMed
    Score: 0.033
  31. CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015 Apr 29; 7(285):285ra63.
    View in: PubMed
    Score: 0.033
  32. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
    View in: PubMed
    Score: 0.031
  33. PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. Am J Hum Genet. 2014 Jul 03; 95(1):96-107.
    View in: PubMed
    Score: 0.031
  34. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
    View in: PubMed
    Score: 0.031
  35. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013 Oct; 174(1):89-96.
    View in: PubMed
    Score: 0.030
  36. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
    View in: PubMed
    Score: 0.029
  37. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.